Patrick Müller

Patrick Müller

Auto-generated profile, based on publicly available information

Patrick Müller

Interfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
LMLisa Maier
Lisa Maier
CGCamille V. Goemans
Camille V. Goemans
JWJakob Wirbel
Jakob Wirbel
MKMichael Kuhn
Michael Kuhn
CEClaudia Eberl
Claudia Eberl
ATAthanasios Typas
Athanasios Typas

16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
AGAnne Grießhammer
Anne Grießhammer
JCJuan Jacobo De la Cuesta-Zuluaga
Juan Jacobo De la Cuesta-Zuluaga
PMPatrick Müller
Patrick Müller
CGCordula Gekeler
Cordula Gekeler
Jan HomolakJan Homolak
Jan Homolak
LMLisa Maier
Lisa Maier
Non-antibiotic drugs can alter the composition of the gut microbiome1, but they have largely unknown implications for human health2. Here we examined how non-antibiotics affect the ability of gut commensals to resist colonization by enteropathogens3. We also developed an in vitro assay to assess enteropathogen growth in drug-perturbed microbial communities. Pathogenic Gammaproteobacteria were more resistant to non-antibiotics than commensals and their post-treatment expansion was potentiated. For 28% of the 53 drugs tested, the growth of Salmonella enterica subsp. enterica serovar Typhimurium. (S. Tm) in synthetic and human stool-derived communities was increased, and similar effects were observed for other enteropathogens. Non-antibiotics promoted pathogen proliferation by inhibiting the growth of commensals, altering microbial interactions and enhancing the ability of S. Tm to exploit metabolic niches. Drugs that promoted pathogen expansion in vitro increased the intestinal S. Tm load in mice. For the antihistamine terfenadine, drug-induced disruption of colonization resistance accelerated disease onset and increased inflammation caused by S. Tm. Our findings identify non-antibiotics as previously overlooked risk factors that may contribute to the development of enteric infections.

13 December 2023 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
PMPatrick Müller
Patrick Müller
JCJuan Jacobo De la Cuesta-Zuluaga
Juan Jacobo De la Cuesta-Zuluaga
MKMichael Kuhn
Michael Kuhn
MAMaral Baghai Arassi
Maral Baghai Arassi
TTTim Treis
Tim Treis
LMLisa Maier
Lisa Maier

16 June 2025 in Gut Microbes
Verified
Journal Article
Open access
JSJulia Schumacher
Julia Schumacher
PMPatrick Müller
Patrick Müller
JSJohannes Sulzer
Johannes Sulzer
FFFranziska Faber
Franziska Faber
BMBastian Molitor
Bastian Molitor
LMLisa Maier
Lisa Maier
Clostridioides difficile infections often occur after antibiotic use, but they have also been linked to proton-pump inhibitor (PPI) therapy. The underlying mechanism - whether infection risk is due to a direct effect of PPIs on the gut microbiome or changes in gastrointestinal pH - has remained unclear. To disentangle both possibilities, we studied the impact of the proton-pump inhibitor omeprazole and pH changes on key members of the human gut microbiome and stool-derived microbial communities from different donors in vitro. We then developed a custom multiple-bioreactor system to grow a model human microbiome community and a stool-derived community in chemostat mode and tested the effects of omeprazole exposure, pH changes, and their combination on C. difficile growth within these communities. Our findings show that changes in pH significantly affect the gut microbial community's biomass and the abundances of different bacterial taxa, leading to increased C. difficile growth within the community. However, omeprazole treatment alone did not result in such effects. These findings imply that the higher risk of C. difficile infection following proton-pump inhibitor therapy is probably because of alterations in gastrointestinal pH rather than a direct interaction between the drug and the microbiome. This understanding offers a new perspective on infection risks in proton-pump inhibitor therapy.

11 October 2024 in Trends in Microbiology
Verified
Journal Article
Open access
JCJuan Jacobo De la Cuesta-Zuluaga
Juan Jacobo De la Cuesta-Zuluaga
PMPatrick Müller
Patrick Müller
LMLisa Maier
Lisa Maier
The human gut microbiome, a community of microbes that plays a crucial role in our wellbeing, is highly adaptable but also vulnerable to drug treatments. This vulnerability can have serious consequences for the host, for example, increasing susceptibility to infections, immune, metabolic, and cognitive disorders. However, the microbiome's adaptability also provides opportunities to prevent, protect, or even reverse drug-induced damage. Recently, several innovative approaches have emerged aimed at minimizing the collateral damage of drugs on the microbiome. Here, we outline these approaches, discuss their applicability in different treatment scenarios, highlight current challenges, and suggest avenues that may lead to an effective protection of the microbiome.

6 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAnne Griesshammer
Anne Griesshammer
JCJuan Jacobo De la Cuesta-Zuluaga
Juan Jacobo De la Cuesta-Zuluaga
TZTaiyeb Zahir
Taiyeb Zahir
PMPatrick Mueller
Patrick Mueller
CGCordula Gekeler
Cordula Gekeler
LMLisa Maier
Lisa Maier
Summary: Non-antibiotic drugs can alter the composition of the gut microbiome, with largely undefined implications for human health. Here we compared the susceptibility of commensal and pathogenic bacteria to non-antibiotic drugs and found that pathogens show higher drug resistance, which could favor their expansion after treatment. We then developed a model system to screen for drug-microbiome interactions that increase the risk of enteropathogenic infections. Approximately 35% of the >50 drugs we tested increased the abundance of Salmonella Typhimurium in synthetic and human stool-derived microbial communities. This was due to direct effects of non-antibiotics on individual commensals, altered microbial interactions within communities and the potential of Salmonella to exploit different metabolic niches. Non-antibiotic drugs that favored Salmonella expansion in vitro also promoted other enteric pathogens and increased Salmonella loads in gnotobiotic and conventional mice. These findings may inform future strategies to control pathogen proliferation and to assess individual microbiota-drug-pathogen risks for infection.